The urokinase plasminogen activator system as a target for prognostic studies in breast cancer.
about
Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision MedicineDetection and clinical importance of micrometastatic disease.Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Can axillary dissection be avoided by improved molecular biological diagnosis?Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditionsNode-Negative Breast Cancer: Which Patients Should Be Treated?Protease nexin-1 expression is altered in human breast cancer.Annexin A2 promotes glioma cell invasion and tumor progressionImmunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.Combined Proteomics and Transcriptomics Identifies Carboxypeptidase B1 and Nuclear Factor κB (NF-κB) Associated Proteins as Putative Biomarkers of Metastasis in Low Grade Breast CancerPEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor.Development of a Mammalian suspension culture for expression of active recombinant human urokinase-type plasminogen activator.Prognostic value of maspin mRNA expression in ER alpha-positive postmenopausal breast carcinomasForkhead transcription factor foxq1 promotes epithelial-mesenchymal transition and breast cancer metastasisHealth economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer.Chickpea (Cicer arietinum) and other plant-derived protease inhibitor concentrates inhibit breast and prostate cancer cell proliferation in vitro.Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study.An ultra-sensitive immunoassay for quantifying biomarkers in breast tumor tissue.Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat.High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI-2) is an independent marker for shorter progression-free survival in patients with early stage endometrial cancer.
P2860
Q28067626-7FC616F4-D2F5-4730-9420-642374D6E220Q33678970-11CE112E-4E3A-4209-AFE5-7D6FE0013202Q33698446-56A22407-B42C-483E-9C1B-D29C69CD3729Q34033291-204146F2-B833-4BC8-86CC-E10E3D8A9CCAQ34217461-527CDC3E-9A87-4DE9-BF65-D84AE66ABDB8Q34284270-34363B6A-82C4-4B47-A0AA-C8A59D8A9178Q34768102-300F920C-A250-4BB7-BE5E-A2606C482E22Q35448499-82295101-07A2-441F-9C6C-1B6A331D7C19Q35745789-280026BB-5AE6-46AB-9A7C-B7D7A5CAA2A2Q36103894-88C3B79C-D0B4-46AB-ABEF-B160D4FED757Q36143607-5F522622-DE31-46FB-8298-BBF350369910Q36255134-CB0D8E2C-6C10-4D6A-B551-41248A235FB1Q36648801-02EFA9FC-01E4-4A2E-BBF1-DDF55C8E9ED1Q37529876-F5356C57-8C06-427B-AB24-84FA70D6E0E6Q38316487-43E88CB0-09B0-468E-8F5A-395FB59489FAQ39337584-DE201279-E37C-4DB0-92CC-581C9F9D1E9CQ40735449-E1123152-CD62-4B7F-A7B0-0FEB013564E2Q41905619-6FEEFD5E-938F-4490-AA1D-93456618E7A5Q43811861-4A028A80-577C-47FB-9F2F-3FD0E566F1EEQ53318958-D24B12DC-3224-410E-A2A3-9CC078FDF2C3
P2860
The urokinase plasminogen activator system as a target for prognostic studies in breast cancer.
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
The urokinase plasminogen acti ...... stic studies in breast cancer.
@ast
The urokinase plasminogen acti ...... stic studies in breast cancer.
@en
The urokinase plasminogen acti ...... stic studies in breast cancer.
@nl
type
label
The urokinase plasminogen acti ...... stic studies in breast cancer.
@ast
The urokinase plasminogen acti ...... stic studies in breast cancer.
@en
The urokinase plasminogen acti ...... stic studies in breast cancer.
@nl
prefLabel
The urokinase plasminogen acti ...... stic studies in breast cancer.
@ast
The urokinase plasminogen acti ...... stic studies in breast cancer.
@en
The urokinase plasminogen acti ...... stic studies in breast cancer.
@nl
P2093
P2860
P356
P1476
The urokinase plasminogen acti ...... stic studies in breast cancer.
@en
P2093
P2860
P2888
P304
P356
10.1023/A:1006115218786
P407
P577
1998-01-01T00:00:00Z
P6179
1036383850